Skip to main content
. 2021 Feb 16;10(5):1525–1534. doi: 10.1002/cam4.3617

TABLE 2.

The agents used for immunotherapy were nivolumab and pembrolizumab.

Immunotherapy agent Number of patients, n = 155 (%)
Nivolumab 151 (97.4)
Pembrolizumab 4 (2.6)
Nivolumab dose
3 mg/kg every 2 weekly 108 (69.7)
240 mg flat dose every 2 weekly 47 (30.3)
Pembrolizumab‐ 200 mg flat dose every 3 weekly 4 (2.6)